Trials / Completed
CompletedNCT04317066
A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)
A Phase 1 Clinical Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (KEYNOTE-A33)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the objective response, safety, and tolerability of pembrolizumab in Japanese participants who have refractory primary mediastinal large B-cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Pembrolizumab 200 mg by intravenous (IV) infusion, given on day 1 of each 3-week cycle. |
Timeline
- Start date
- 2020-06-26
- Primary completion
- 2024-04-11
- Completion
- 2024-04-11
- First posted
- 2020-03-20
- Last updated
- 2025-04-06
- Results posted
- 2025-04-06
Locations
9 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04317066. Inclusion in this directory is not an endorsement.